Use of MiniMed 780G System in Children and Adolescents
- Conditions
- Diabetes
- Registration Number
- NCT05591690
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Hybrid closed-loop technology have shown that it improves glycemic control parameters, but the investigators do not have sufficient data at more than 6 months of follow-up, allowing us to describe the effectiveness of these systems in the long term.
All MiniMed 780G system users from November 2020 to March 2022 were included (n=32) For every time points, there was a significant difference in Time In Range between the pre-AHCL and post-AHCL. Noted difference were +14.5% and, +10.8% at respectively 3 months and 1 year. No more hypoglycemia were identified.
This "real-life" analysis shows that the algorithm is effective in improvement of metabolic control for T1 diabetic children and adolescents, at one year of follow-up.
However, an effect of breathlessness is observed which underlined the need for a solid therapeutic education program.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time spent with glucose levels below range 1 year Time spent with glucose levels inferior to 70mg/dL
Time spent with glucose levels above range 1 year Time spent with glucose levels superior to 180 mg/dL
Glycated hemoglobin 1 year Percentage of glycated hemoglobin measured by the MiniMed 780G system
Time spent in range Level with glucose levels within the norm 1 year Time spent with glucose levels between 70 and 180 mg/dL
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Uhmontpellier
đŸ‡«đŸ‡·Montpellier, France